The conflicting results may be attributed in part to different methods, such as the use of mass spectrometry (MS) or immunohistochemistry (IHC) to measure protein expression and highlight the need for further comprehensive studies to conclusively clarify the role and expression patterns of DNMT1, DNMT3A, and TDG at different stages of tumor development. The gene discussed is DNMT3A; the disease is neoplasm.